Skip To Main Content
Lilly
Menu closed
Lilly
    Lilly

    You are now leaving the LillyMedical website

    The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
    Click "Continue" to proceed or "Return" to return to LillyMedical.

    Obesity Journal Publications

    This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

    If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here

    For all other requests, please visit our Contact Lilly services.

    Zepbound® (tirzepatide)

    Full Prescribing Information

    Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes
    Published Date: March 01, 2023
    Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Published Date: June 08, 2022
    Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Published Date: March 29, 2021
    The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists
    Published Date: June 10, 2020

    Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
    Published Date: June 08, 2024
    Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
    Published Date: May 20, 2024
    Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
    Published Date: June 27, 2020

    Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
    Published Date: November 18, 2024
    Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity.
    Published Date: November 18, 2024
    Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
    Published Date: November 17, 2024
    Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    Published Date: November 16, 2024
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    Published Date: November 13, 2024
    Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.
    Published Date: September 16, 2024
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    Published Date: June 21, 2024
    Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
    Published Date: May 31, 2024
    Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial.
    Published Date: March 26, 2024
    Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index >/=27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.
    Published Date: February 05, 2024
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Published Date: June 26, 2023
    Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
    Published Date: October 15, 2023
    Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial.
    Published Date: December 11, 2023
    Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program.
    Published Date: December 7, 2022

    No Publication Journals

    The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes.
    Published Date: February 23, 2023
    Five-Year Morbidity and Mortality Rates in a U.S. Population with Obesity with and without Prediabetes
    Published Date: May 3, 2023
    Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data
    Published Date: May 31, 2023
    Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review.
    Published Date: March 11, 2022
    Anti-obesity Medication Use Among Adults with Overweight and Obesity in the United States: 2015-2018.
    Published Date: July 12, 2021
    Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.
    Published Date: August 24, 2021

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Consumer Health Privacy Notice
    • Accessibility Statement
    • Sitemap
       

      This site is intended for US Healthcare Professionals only.

      4.0.68 6/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
      Cookie Settings
      Facebook X LinkedIn
      Lilly